metformin + repaglinide
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
84
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Diabetes
Conditions
Diabetes, Diabetes Mellitus, Type 2
Trial Timeline
Mar 6, 2002 โ Oct 21, 2004
NCT ID
NCT01465152About metformin + repaglinide
metformin + repaglinide is a approved stage product being developed by Novo Nordisk for Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT01465152. Target conditions include Diabetes, Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01465152 | Approved | Completed |
Competing Products
20 competing products in Diabetes